Xtrem Biotech
-
DATABASE (95)
-
ARTICLES (44)
CEO and founder of Mycorena
Ramkumar Nair graduated in biotechnology at the Cochin University of Science and Technology in Kerala before going to Sweden for postgrad studies in 2013.During his PhD in industrial biotechnology at the University of Borås, he embarked on a research project to create fungi-based proteins from discarded sidestreams generated by food producers. After extensive research in 2017, he founded Mycorena in Gothenburg to produce mycoproteins using fermentation technology.The startup’s first commercial product, Promyc, is now being sold to global food companies as a more sustainable and nutritional alt-protein compared to traditional plant-based proteins.
Ramkumar Nair graduated in biotechnology at the Cochin University of Science and Technology in Kerala before going to Sweden for postgrad studies in 2013.During his PhD in industrial biotechnology at the University of Borås, he embarked on a research project to create fungi-based proteins from discarded sidestreams generated by food producers. After extensive research in 2017, he founded Mycorena in Gothenburg to produce mycoproteins using fermentation technology.The startup’s first commercial product, Promyc, is now being sold to global food companies as a more sustainable and nutritional alt-protein compared to traditional plant-based proteins.
CTO and Co-founder of Oceanium
Charlie Bavington holds a PhD in biochemistry from the University of Edinburgh and has done postdoctoral research at the Scottish Association for Marine Science in natural marine products specializing in glycobiology and carbohydrate chemistry.In 2000, he moved from academic research to industry, joining a marine biotechnology company where he has been responsible for natural product discovery and contract research. His commitment to marine life and natural product development continued with GlycoMar, a company he co-founded in 2005, specializing in the discovery and development of novel functional glycans from microalgae, macroalgae, invertebrates, and plants.Since 2018, he’s CTO and co-founder of Oceanium, a Scottish startup developing marine-safe bio-packaging and plant-based food and nutrition products from sustainably farmed seaweed.
Charlie Bavington holds a PhD in biochemistry from the University of Edinburgh and has done postdoctoral research at the Scottish Association for Marine Science in natural marine products specializing in glycobiology and carbohydrate chemistry.In 2000, he moved from academic research to industry, joining a marine biotechnology company where he has been responsible for natural product discovery and contract research. His commitment to marine life and natural product development continued with GlycoMar, a company he co-founded in 2005, specializing in the discovery and development of novel functional glycans from microalgae, macroalgae, invertebrates, and plants.Since 2018, he’s CTO and co-founder of Oceanium, a Scottish startup developing marine-safe bio-packaging and plant-based food and nutrition products from sustainably farmed seaweed.
Senior Scientific Advisor and co-founder of The Not Company (NotCo)
Pablo Zamora is a biotechnologist from the University of Santiago, where he worked as a professor and research scientist until 2008. In 2009, he started his postdoctoral research on Mexico’s maize genetics at UC Davis Life Science Innovation Center. He worked there as a senior scientist and associate until 2014. In 2015, he was appointed the center’s Chief Science Officer based in Chile, a position he was in till January 2018.From 2013–2015, he also worked on various plant and microbe genomics projects as a senior scientist in Mars Advanced Research Institute. He was also an editor from 2012–2017 at the Journal of Technology Management & Innovation and worked at the non-profit PIPRA from 2010–2018 as international alliance manager in Sacramento, University of California.In 2015, he co-founded The Not Company (NotCo) based in Santiago. He was appointed CSO in February 2018, a role he led until March 2020, when he left the company to focus on a new project, AptaBuilder, a $60m program that promotes R&D for Chilean technology-based ventures. Zamora still consults as NotCo’s senior scientific advisor.
Pablo Zamora is a biotechnologist from the University of Santiago, where he worked as a professor and research scientist until 2008. In 2009, he started his postdoctoral research on Mexico’s maize genetics at UC Davis Life Science Innovation Center. He worked there as a senior scientist and associate until 2014. In 2015, he was appointed the center’s Chief Science Officer based in Chile, a position he was in till January 2018.From 2013–2015, he also worked on various plant and microbe genomics projects as a senior scientist in Mars Advanced Research Institute. He was also an editor from 2012–2017 at the Journal of Technology Management & Innovation and worked at the non-profit PIPRA from 2010–2018 as international alliance manager in Sacramento, University of California.In 2015, he co-founded The Not Company (NotCo) based in Santiago. He was appointed CSO in February 2018, a role he led until March 2020, when he left the company to focus on a new project, AptaBuilder, a $60m program that promotes R&D for Chilean technology-based ventures. Zamora still consults as NotCo’s senior scientific advisor.
CEO and and co-founder of Bluepha
Zhang Haoqian completed a doctorate degree in systems and synthetic biology at Peking University in 2016. He has published more than 20 papers in international academic journals. In 2019, he was honored as one of China's 100 Most Creative People in Business. He is also a member of the Synthetic Biology Committee under China Society of Biotechnology.Peking University has participated in the International Genetically Engineered Machine (iGEM) competitions, with Zhang as a team member or leader between 2008 and 2010. The team has won gold medals twice at the iGEM competitions supported by MIT. He was also coaching the university’s iGEM team from 2011 until 2017. Zhang also founded the committee of China iGEMer Community.In 2010, Zhang met fellow iGEMer and Bluepha co-founder Li Teng at the iGEM giant jamboree event. They co-founded SynBio startup Bluepha in 2016, a spin-off from Tsinghua University.
Zhang Haoqian completed a doctorate degree in systems and synthetic biology at Peking University in 2016. He has published more than 20 papers in international academic journals. In 2019, he was honored as one of China's 100 Most Creative People in Business. He is also a member of the Synthetic Biology Committee under China Society of Biotechnology.Peking University has participated in the International Genetically Engineered Machine (iGEM) competitions, with Zhang as a team member or leader between 2008 and 2010. The team has won gold medals twice at the iGEM competitions supported by MIT. He was also coaching the university’s iGEM team from 2011 until 2017. Zhang also founded the committee of China iGEMer Community.In 2010, Zhang met fellow iGEMer and Bluepha co-founder Li Teng at the iGEM giant jamboree event. They co-founded SynBio startup Bluepha in 2016, a spin-off from Tsinghua University.
CEO and co-founder of TurtleTree Labs
Cheese connoisseur, Lin Fengru, was unable to find milk that allowed her to make high-quality cheese. During her search around dairy farms in Asia, she realized that the poor quality of the milk was due to animal hygiene issues and the use of antibiotics and hormones on cows. The lack of quality dairy milk options inspired her to co-found TurtleTree Labs in January 2019 to create milk using stem cells.Lin graduated in information systems management and marketing in 2011 at Singapore Management University (SMU). In 2011, she joined Collis Asia as an account manager and left in 2014 to work at Salesforce in sales and business development. She joined Google Singapore in 2018 and worked as a territory account manager for Google Cloud Platform until June 2019. In 2020, she completed an MIT course in the science and business of biotechnology.
Cheese connoisseur, Lin Fengru, was unable to find milk that allowed her to make high-quality cheese. During her search around dairy farms in Asia, she realized that the poor quality of the milk was due to animal hygiene issues and the use of antibiotics and hormones on cows. The lack of quality dairy milk options inspired her to co-found TurtleTree Labs in January 2019 to create milk using stem cells.Lin graduated in information systems management and marketing in 2011 at Singapore Management University (SMU). In 2011, she joined Collis Asia as an account manager and left in 2014 to work at Salesforce in sales and business development. She joined Google Singapore in 2018 and worked as a territory account manager for Google Cloud Platform until June 2019. In 2020, she completed an MIT course in the science and business of biotechnology.
Co-Stone is one of the earliest venture capital firms in China, with about RMB 30 billion in assets under management today. It operates growth-stage investments and pre-IPO financings, focusing on TMT, biotechnology, consumer and services sectors in China. It has invested in more than 80 companies, where Co-Stone was the lead investor in over 60% of the financings.
Co-Stone is one of the earliest venture capital firms in China, with about RMB 30 billion in assets under management today. It operates growth-stage investments and pre-IPO financings, focusing on TMT, biotechnology, consumer and services sectors in China. It has invested in more than 80 companies, where Co-Stone was the lead investor in over 60% of the financings.
Haitong Kaiyuan Investment is the wholly owned private equity investment firm by Haiting Securities in 2008. It focuses on new energy, new material, biotechnology, IT, communication and advanced manufacturing sectors.
Haitong Kaiyuan Investment is the wholly owned private equity investment firm by Haiting Securities in 2008. It focuses on new energy, new material, biotechnology, IT, communication and advanced manufacturing sectors.
Aqua-Spark is a Netherlands-based fund that supports aquaculture businesses around the world, with the vision to create profitable aquaculture ventures that can help to restore ocean ecosystems that have been damaged by overfishing. Its portfolio covers a wide range of enterprises, ranging from low-cost fish farms in Madagascar to biotechs and high tech aquaculture companies.
Aqua-Spark is a Netherlands-based fund that supports aquaculture businesses around the world, with the vision to create profitable aquaculture ventures that can help to restore ocean ecosystems that have been damaged by overfishing. Its portfolio covers a wide range of enterprises, ranging from low-cost fish farms in Madagascar to biotechs and high tech aquaculture companies.
Founded in 2016, SDICVC is a fund management company under State Development & Investment Corp, dedicating itself to promoting the industrialization of advanced technology and innovation in China, with key focus in Clean Technology, New Energy, Advanced Biotechnology, Advanced IT & Electronic Science. SDICVC currently manages 3 major funds, namely, National Science and Technology Major Project Fund, JingJinJi (Beijing, Tianjin, Hebei) Special Fund and High-Tech (Shenzhen) Startup Fund, backing up 30 Chinese startups in the related fields.
Founded in 2016, SDICVC is a fund management company under State Development & Investment Corp, dedicating itself to promoting the industrialization of advanced technology and innovation in China, with key focus in Clean Technology, New Energy, Advanced Biotechnology, Advanced IT & Electronic Science. SDICVC currently manages 3 major funds, namely, National Science and Technology Major Project Fund, JingJinJi (Beijing, Tianjin, Hebei) Special Fund and High-Tech (Shenzhen) Startup Fund, backing up 30 Chinese startups in the related fields.
Born in Shanghai in 1973, Zhang and his parents immigrated to the US in 1987. He received his bachelor’s in Neurobiology from the University of California, San Francisco in 1995 and his master’s in Biotechnology and Business from Northwestern University in 1999. Zhang worked at Salomon Smith Barney and ABN AMRO Capital from 1999–2001. He then served as managing director and head of China operations at venture capital firm WI Harper Group from 2002–2008. Zhang has since served as founding managing partner at Matrix Partners China.
Born in Shanghai in 1973, Zhang and his parents immigrated to the US in 1987. He received his bachelor’s in Neurobiology from the University of California, San Francisco in 1995 and his master’s in Biotechnology and Business from Northwestern University in 1999. Zhang worked at Salomon Smith Barney and ABN AMRO Capital from 1999–2001. He then served as managing director and head of China operations at venture capital firm WI Harper Group from 2002–2008. Zhang has since served as founding managing partner at Matrix Partners China.
Besides being an investor, Evolution Venture Partners provides effective solutions for VCs and their portfolio companies in looking for a capital raise, a strategic transaction, or in the event that the board decides to wind a company down. Established in 2008, Evolution has invested in the US, Europe and in emerging markets and has a special interest in information security, enterprise software and solutions, consumer products. healthcare and biotechnology.
Besides being an investor, Evolution Venture Partners provides effective solutions for VCs and their portfolio companies in looking for a capital raise, a strategic transaction, or in the event that the board decides to wind a company down. Established in 2008, Evolution has invested in the US, Europe and in emerging markets and has a special interest in information security, enterprise software and solutions, consumer products. healthcare and biotechnology.
WuXi AppTec is a Chinese company that specializes in the outsourcing of R&D in the pharmaceuticals, biotechnology and medical devices sectors. Listed on the Hong Kong Stock Exchange, WuXi AppTec has invested in drug development and healthcare firms globally. Its portfolio includes Insilico Medicine, which is developing an AI platform for drug development, brain disease research firm Verge Genomics and Indonesian healthcare platform Halodoc.
WuXi AppTec is a Chinese company that specializes in the outsourcing of R&D in the pharmaceuticals, biotechnology and medical devices sectors. Listed on the Hong Kong Stock Exchange, WuXi AppTec has invested in drug development and healthcare firms globally. Its portfolio includes Insilico Medicine, which is developing an AI platform for drug development, brain disease research firm Verge Genomics and Indonesian healthcare platform Halodoc.
Junrun Capital was founded in 2009 in Ningbo, Zhejiang province. It's the largest private equity fund in Ningbo and specializes in M&A, equity and venture capital investments. So far, it has successfully exited seven deals out of a total of 21. Junrun has investment managers and researchers with backgrounds in science and technology. It has offices in Hangzhou, Shanghai, Shenzhen and the US. The company mainly seeks investment opportunities in sustainable materials, cleantech, agriculture, manufacture, biotechnology and the dotcom economy.
Junrun Capital was founded in 2009 in Ningbo, Zhejiang province. It's the largest private equity fund in Ningbo and specializes in M&A, equity and venture capital investments. So far, it has successfully exited seven deals out of a total of 21. Junrun has investment managers and researchers with backgrounds in science and technology. It has offices in Hangzhou, Shanghai, Shenzhen and the US. The company mainly seeks investment opportunities in sustainable materials, cleantech, agriculture, manufacture, biotechnology and the dotcom economy.
An experienced private investor, Chen Yuxing is a shareholder of over 12 companies including Hangzhou Bailing (Biolynx) Biotechnology Co Ltd and Hangzhou HuaAn Biotechnology Co Ltd (HuaBio).
An experienced private investor, Chen Yuxing is a shareholder of over 12 companies including Hangzhou Bailing (Biolynx) Biotechnology Co Ltd and Hangzhou HuaAn Biotechnology Co Ltd (HuaBio).
Established in 1995 by Sean O'Sullivan, SOSV is a venture capital firm with six attached accelerator programs. Upon receiving investment from SOSV, portfolio companies join one of the accelerator programs that best suits their products. The accelerators are: Chinaccelerator, focused on the Chinese market; Indie Bio, supporting biotechnology and life sciences companies; Food-X, for food-tech and agriculture-focused companies; dlab, which supports startups exploring blockchain and decentralized tech; HAX, for IoT, robotics and other hardware-focused startups; and MOX, an accelerator specializing in mobile platforms and technologies. SOSV, along with the O'Sullivan Foundation, has also provided support for education initiatives such as Khan Academy and CoderDojo (which teaches coding skills to youth).
Established in 1995 by Sean O'Sullivan, SOSV is a venture capital firm with six attached accelerator programs. Upon receiving investment from SOSV, portfolio companies join one of the accelerator programs that best suits their products. The accelerators are: Chinaccelerator, focused on the Chinese market; Indie Bio, supporting biotechnology and life sciences companies; Food-X, for food-tech and agriculture-focused companies; dlab, which supports startups exploring blockchain and decentralized tech; HAX, for IoT, robotics and other hardware-focused startups; and MOX, an accelerator specializing in mobile platforms and technologies. SOSV, along with the O'Sullivan Foundation, has also provided support for education initiatives such as Khan Academy and CoderDojo (which teaches coding skills to youth).
Xtrem Biotech, an agritech startup from Granada, seeks global expansion
With its research roots in the University of Granada, Xtrem Biotech was named one of the world's most innovative agtech spin-offs by accelerator TERRA Food & AgTech
Daniel Oliver: Building a "Facebook" for investments in biotech startups
The biologist and crowdfunding expert has pioneered the growth of Spanish biotech startups, providing access to early-stage investments, with support from scientific experts worldwide
Meatable: Cell-based meat startup secures $47m Series A for scalable technology
The Dutch startup offers a pioneering technology for quickly scaling cell-based meat production while eliminating the need for animal-derived growth media
Forget solar panels and batteries, Bioo wants to scale soil bioelectricity generation
Improving on NASA’s microbial fuel cell tech, Bioo hopes to boost crop efficiency and transform the way urbanites live, in future green cities powered by plants
TurtleTree Labs: Creating sustainable mammalian milk alternatives from stem cells
Founder’s search for high-quality dairy milk led to the creation in a lab of naturally occurring ingredients found in human milk for supply to dairy milk and infant formula businesses
Sequoia Capital China holds steady with investments in healthcare, biotech and green economy
China’s most active investor increases bets on sectors beyond the consumer internet and edtech recently hurt by regulatory clampdown
Because Animals: Pioneering cultured meat for pets
The biotech startup is disrupting the pet food processing industry with cell-based food to minimize environmental “pawprints” and promote animal welfare
NovoNutrients: Tackling the dual problems of CO2 emissions and over-fishing
The first to transform CO2 to fish food, NovoNutrients is trialing with industry giants Skretting and Chevron, and will soon raise Series A funding
Poliloop: Tackling pollution crisis with plastic-eating bacteria for industrial use
Hungarian biotech Poliloop is closing $2m seed funding for “bacteria cocktail” that breaks down plastic into organic waste quickly, enabling more affordable and eco-friendly waste management
Qorium: Lab-grown premium leather for the future of luxury
The Dutch biotech startup co-founded by cell-based meat pioneer Mark Post is targeting the luxury goods market with its “clean leather” sheets made from cultivating bovine skin cells, and plans to raise up to €100m
Mycorena: Fungi-based vegan protein challenging traditional plant-based ingredients
Award-winning Swedish biotech startup is scaling production of mycoprotein to become a key player in the emerging market for functional proteins
TreeFrog Therapeutics: Mimicking how stem cells grow in the human body
The French biotech’s proprietory technology to cultivate pluripotent stem cells in a 3D environment can be scaled to mass-produce high-quality cells to treat diseases such as Parkinson’s
New Food Invest: Opportunities in the European alt-protein space
With a record €2.4bn investment in 2019, Europe’s foodtech sector appears poised for continued growth, but startups, corporations, governments and even universities can do more, experts say
Future Food Asia by ID Capital: Introducing Asia's agrifood startups to the world
More than a meeting of startups and investors, the conference showcases ID Capital’s investment thesis and Big Ag’s support for agrifood tech in the world’s most populous region
Cubiq Foods: Bioreactor farms producing the food of tomorrow
Growing appetite for meat alternatives expected to fuel demand for Cubiq’s low calorie, Omega 3-enriched lab-grown fats
Sorry, we couldn’t find any matches for “Xtrem Biotech”.
